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Outcomes of Sleeve Lobectomy versus 
Pneumonectomy for Lung Cancer
H o n g - K y u  L e e ,  M . D . * ,  H e e - S u n g  L e e ,  M . D . * * ,  K u n - I l  K i m ,  M . D . * ,  H o-Seung  Shin,  M.D.***, 
Jae-Woong  Lee,  M.D.*,  Hyoung-Soo  Kim,  M.D.****,  Sung-Woo  Cho,  M.D.*****
Background:  Sleeve lobectomy for lung cancer in close proximity to or involving the carina is widely accepted. 
Operative morbidity and mortality rates, recurrence, and survival rates have varied considerably across studies. 
Materials and Methods: From March of 2005 to July of 2010, sleeve lobectomy was performed in 19 patients 
and pneumonectomy was performed in 20 patients. In this paper, the results of sleeve lobectomy and pneumo-
nectomy for patients with lung cancer will be compared and evaluated. Results: There were no postoperative com-
plications in either group, but there was one mortality in the pneumonectomy group. There was better preservation 
of pulmonary function in the sleeve lobectomy group than the pneumonectomy group (p=0.066 in FVC, p=0.019 in 
FEV1). The 3-year survival rates were 46.7% in the sleeve lobectomy group and 54.5% in the pneumonectomy 
group (p=0.505). The 3-year disease-free survival rates were 38% in the sleeve lobectomy group and 45.8% in the 
pneumonectomy group (p=0.200). Conclusion: Sleeve lobectomy for lung cancer showed low mortality, low bronchial 
anastomotic complication rates, and good preservation of pulmonary function.
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INTRODUCTION
Sleeve  lobectomy  is  removal  of  the  part  of  the  main  stem 
bronchus  in  continuity  with  the  adjacent  lobe  or  bilobe  fol-
lowed by end-to-end bronchial anastomosis [1]. Since the first 
report by Price-Thomas [2], sleeve lobectomy has been wide-
ly  used  to  treat  patients  with  lung  cancer  in  close  proximity 
to  or  involving  the  carina  [3-6].  Since  sleeve  lobectomy 
yielded  survival  results  at  least  equal  to  those  of  pneumo-
nectomy, as well as better functional results, it became an ac-
cepted procedure for patients with lung cancer who have ana-
tomically  suitable  tumors,  regardless  of  lung  function  [7-9]. 
Functional  lung  parenchyma  can  be  preserved,  and  the  re-
implanted  lobes  contribute  to  postoperative  quality  of  life.  If 
a  second  case  of  primary  lung  cancer  develops,  subsequent 
resection may be offered to selected patients [10,11]. Howev-
er,  bronchial  anastomotic  complications  and  operative  mortal-
ity  rates  show  considerable  variation  across  studies  [12,13]. Hong-Kyu Lee, et al
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Table 1. Type of resection
  Sleeve  lobectomy Pneumonectomy
Right
  R U L
  R L L
  R M L ＋RLL
Left
  L U L
    LLL
Total
 
7
1
3
 
2
6
19
 7
13
20
RUL=Right  upper  lobe;  RLL=Right  lower  lobe;  RML=Right 
middle  lobe;  LUL=Left  upper  lobe;  LLL=Left  lower  lobe.
We  performed  this  study  to  determine  the  outcomes  of  our 
use  of  sleeve  lobectomy  for  primary  lung  cancer.
MATERIALS AND METHODS
Between March 2005 and July 2010, 19 patients underwent 
sleeve  lobectomy  and  20  patients  underwent  pneumonectomy 
for primary lung cancer. In the sleeve lobectomy group, there 
were  14  men  and  5  women,  with  a  mean  age  of  62.1±8.9 
years  (range,  41  to  75  years).  In  the  pneumonectomy  group, 
there  were  16  men  and  4  women,  with  a  mean  age  of 
64.3±8.8  years  (range,  46  to  81  years).  The  decision  to  per-
form  sleeve  lobectomy  was  based  on  the  preoperative  bron-
choscopic  evaluation in  18 patients  and  was  made  during  the 
operation in 1 patient who had bronchial margin involvement 
determined  by  frozen-section  examination. 
Tumor  spread  and  functional  status  were  evaluated 
preoperatively.  Physical  examination,  chest  X-ray,  chest  com-
puted  tomography  (CT),  18F-Fluorodeoxyglucose  positron 
emission  tomography  (FDG-PET),  spirometry,  arterial  blood 
gases,  and  quantitative  ventilation  and  perfusion  scans  were 
performed  routinely  to  evaluate  functional  status.  Patients  at 
high  risk  for  heart  disease  were  screened  by  echocardio-
graphy.  Tumor  spread  to  the  airway  was  evaluated  by  fiber-
optic  bronchoscopy,  which  plays  a  key  role  in  selecting  pa-
tients for sleeve lobectomy; patients who have submucosal in-
vasion or extrinsic compression of a lobar orifice with a pos-
itive  elective  biopsy  are  good  candidates  for  sleeve  lobec-
tomy. 
Single-lung ventilation was established through a double-lu-
men endotracheal tube. A posterolateral thoracotomy was per-
formed  in  the  fifth  intercostal  space.  The  hilar,  carinal,  para-
tracheal,  esophageal,  and  inferior  pulmonary  ligament  lymph 
nodes  were  routinely  dissected.  In  sleeve  resection,  circum-
ferential  bronchial  resection  was  performed  with  a  knife  to 
obtain  a  straight  margin  distance  from  the  tumor.  Specimens 
of the resection margins were taken for frozen-section exami-
nation  to  ensure  complete  resection  and  provide  that  ex-
tension  to  sleeve  lobectomy  was  feasible.  Most  patients  were 
extubated  in  the  operating  room  after  the  procedure.  When 
postoperative mechanical ventilation was necessary, a standard 
endotracheal  tube  was  substituted  for  the  double-lumen  tube.
Patients were followed up by routine chest X-ray and chest 
CT  scans.  Fiberoptic  bronchoscopy  was  performed  routinely 
in  all  patients  before  discharge  between  day  7  and  10,  and 
when  atelectasis  indicated.  1  month  after  surgery,  a  pulmo-
nary function test was performed. Operative mortality was de-
fined  as  death  within  30  days  of  the  operation  or  death  di-
rectly  related  to  the  surgical  procedure.
Findings  from  follow-up  investigations  were  used  to  cate-
gorize  recurrences  as  in  the  anastomosed  area,  regional,  or 
distant.
The  data  were  compared  with  the  independent  t-test. 
Survival  data  were  calculated  according  to  the  Kaplan-Meier 
method from the date of operation and included postoperative 
deaths. Any value of p less than 0.05 was considered statisti-
cally  significant.
RESULTS
In the sleeve lobectomy group, there were 7 right upper lo-
b e c t o m i e s ,  1  r i g h t  l o w e r  l o b e c t o m y ,  3  b i l o b e c t o m i e s ,  2  l e f t  
upper lobectomies, and 6 left lower lobectomies. In the pneu-
monectomy group, there were 13 left pneumonectomies and 7 
right  pneumonectomies  (Table  1).  The  permanent  sections 
showed  squamous  cell  cancer  in  13  patients  (68.4%),  ad-
enocarcinoma  4  in  patients  (21%),  and  other  types  of  cancer 
in 2 patients (10.5%) in the sleeve lobectomy group, and squ-
amous cell cancer in 14 patients (70%), adenocarcinoma in 4 
patients  (20%),  and  other  types  in  2  patients  (10%)  in  the 
pneumonectomy  group.  According  to  the  TNM  classification, 
in  the  sleeve  lobectomy  group, 5  p a t i e n t s  ( 2 6 . 3 % )  w e r e  i n  Sleeve Lobectomy versus Pneumonectomy for Lung Cancer
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Table 2. Comparison of clinical variables of the sleeve lobectomy 
and pneumonectomy groups
Sleeve 
lobectomy
Pneumonectomy
Sex 
  M a l e
  F e m a l e
Diagnosis
    Squamous  cell  carcinoma
    Adenocarcinoma
  O t h e r
Postoperative  Staging
  I a / I b
    IIa/IIb
    IIIa/IIIb
Adjuvant  therapy
  R a d i a t i o n
    Chemotherapy
  B o t h
15
 4
13
 4
 2
2/3
5/3
 6
13
 2
 5
 6
16
 4
14
 4
 2
0/8
2/3
6/1
15
 1
 9
 5
Table 3. Pulmonary function test 
Sleeve 
lobectomy
Pneumonec-
tomy
p-value
Mean  FVC  (postoperative/ 
preoperative)
Mean  FEV1  (postoperative/ 
preoperative)
2.87/3.22
(89.1%)
1.99/2.13
(93.4%)
2.36/3.32
(71.0%)
1.74/2.40
(72.5%)
0.066
0.019
FVC=Forced  vital  capacity;  FEV1=Forced  expiratory  volume  in 
one  second.
Table 4. Patterns of recurrence
Sleeve  lobectomy Pneumonectomy
Anastomosis  site
Regional 
Distant
Locoregional＋distant
Total
0
2
2
1
5
0
2
5
2
9
s t a g e  I  ( 2  I A  a n d  3  I B ) ,  8  ( 4 2 . 1 % )  w e r e  i n  s t a g e  I I  ( 5  I I A  
and  3  IIB),  and  6  (31.5%)  were  in  stage  III  (6  IIIA).  4  pa-
tients  (21%)  had  T1,  11  (57.8%)  T2,  3  (15.7%)  T3,  and  1 
(5.2%) T4 disease. 10 (52.6%) had N0, 5 (26.3%) N1, and 4 
(21%)  N2  disease.  In  the  pneumonectomy  group,  8  patients 
(40%) were in stage I (8 IB), 5 (25%) in stage II (2 IIA and 
3  IIB),  and  7  (35%)  in  stage  III  (6  IIIA  and  1  IIIB).  1  pa-
tient (5%) had T1, 14 (70%) T2, 4 (20%) T3, and 1 (5%) T4 
disease. 10 (50%) had N0, 4 (20%) N1, and 6 (30%) N2 dis-
ease  (Table  2).
In  the  sleeve  lobectomy  group ,  1  p a t i e n t  h a d  i n c o m p l e t e  
resection  in  which  frozen  sections  of  the  bronchial  margin 
were positive but pneumonectomy was contraindicated by the 
results  of  preoperative  investigations.  In  the  pneumonectomy 
group,  all  patients  underwent  complete  resection.  In  the 
sleeve  lobectomy  group,  postoperative  radiation  therapies 
were  used  in  2  patients  and  postoperative  chemotherapies 
were  used  in  5  patients.  6  patients  received  both  chemo-
therapy  and  radiation  therapy  after  the  operations.  In  the 
pneumonectomy  group,  postoperative  radiation  therapy  was 
used in 1 patient and postoperative chemotherapy was used in 
9  patients.  5  patients  received  both  chemotherapy  and  radia-
tion  therapy  after  the  operation  (Table  2).  There  were  no 
postoperative complications in either group, but there was one 
mortality  associated  with  the  operation,  repiratory  failure  in 
the  pneumonectomy  group.  In  the  sleeve  lobectomy  group,  a 
preoperative  pulmonary  function  test  showed  mean  values  of 
f o r c e d  e x p i r a t o r y  v o l u m e  i n  1  s e c o n d  ( F E V 1 )  a n d  f o r c e d  v i -
tal  capacity  (FVC),  of  2.13  L  and  3.22  L,  repectively.  The 
mean values of FEV1 and FVC showed 1.99 L and 2.87 L 1 
month  after  surgery,  with  no  significant  difference  (p=0.605 
and  p=0.377,  respectively).  In  the  pneumonectomy  group,  the 
mean  values  of  FEV1  and  FVC  decreased  from  2.40  L  to 
1.74 L and 3.32 L to 2.36 L 1 month after surgery, with sig-
nificant  changes  both  p=0.002.  There  was  better  preservation 
of pulmonary function in the sleeve lobectomy group than the 
pneumonectomy  group  (89.1%  of  mean  FVC  and  93.4%  of 
mean  FEV1  in  the  sleeve  lobectomy  group,  71%  of  mean 
FVC  and  72.5%  of  mean  FEV1  in  the  pneumonectomy 
group)  (Table  3).
In  the  sleeve  lobectomy  group,  the  site  of  recurrence  was 
the  anastomosis  site  in  0,  regional  in  2,  distant  in  2,  and  lo-
coregional and distant in 1. In the pneumonectomy group, the 
site of recurrence was regional in 2, distant in 5, and locore-
gional  and  distant  in  2  (Table  4).  The  3-year  survival  rates 
were 46.7% in  the  sleeve lobectomy  group  and  54.5%  in the 
pneumonectomy  group  (p=0.505)  (Fig.  1).  The  3-year  dis-
ease-free  survival  rates  were  38%  in  the  sleeve  lobectomy Hong-Kyu Lee, et al
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Fig. 1. Three-year overall survival. Fig. 2. Three-year recurrence-free survival.
group  and  45.8%  in  the  pneumonectomy  group  (p=0.200) 
(Fig.  2). 
DISCUSSION
Since  the  first  report  by  Price-Thomas  [2],  sleeve  lobec-
tomy  has  been  generally  used  to  treat  patients  with  central 
bronchogenic  cancer  [3-6].  However,  bronchial  anastomotic 
complications  and  operative  mortality  rates  show  significant 
variation  across  studies  [12,13].  Furthermore,  the  long-term 
results  of  sleeve  resection  in  comparison  with  conventional 
lung cancer resections remain controversial, especially regard-
ing  nodal  involvement  and  functional  status  [14].
The  major  complications  after  performing  sleeve  resection 
were  the  narrowing  of  the  bronchoplasty  site  and  atelectasis, 
whereas  the  pneumonectomy  group  suffered  primarily  from 
postpneumonectomy  empyema  and  respiratory  failure.
A  1992  collective  review  of  1,915  bronchoplastic  proce-
dures  performed  during  a  12-year  period  in  patients  with 
bronchogenic  tumors  found  that  sleeve  lobectomy  was  fol-
lowed  by  morbidity  and  mortality  similar  to  pneumonectomy 
but  allowed  for  better  lung  function  preservation  [3].  In  re-
cent studies, operative mortality has ranged from 0% to 5.2% 
[4,6],  which  is  comparable  to  the  range  after  standard  lobec-
tomy  [15]  and  lower  than  after  standard  pneumonectomy 
[13,16].  In  our  study,  there  was  no  operative  mortality  after 
sleeve  lobectomy.
Specific  procedure-related  complications  of  bronchoplasty 
include  impaired  anastomotic  healing  and  retention  of  bron-
chial  secretions.  The  incidence  of  anastomotic  dehiscence  is 
estimated  at  approximately  3.5%  [3]  and  reoperative  manage-
ment is rarely required. Bronchial ischemia is obvious follow-
ing  sleeve  bronchoplasty.  Reports  of  the  overall  incidence  of 
stenosis range from 3 to 9% [3]. Retention of secretions may 
be  associated  with  bronchial  denervation,  which  has  been 
shown  to  decrease  mucociliary  clearance  and  viscoelasticity 
of  bronchial  secretions  [17].  The  reported  incidence  varies 
f r o m  4  t o  1 2 %  [ 1 8 ] .  W e  d i d  n o t  p e r f o r m  r e p e t i t i v e  b r o n c h o -
scopy  for  bronchial  clearing,  and  there  were  no  postoperative 
complications.
The risk of local recurrence is the main concern caused by 
the  use  of  sleeve  lobectomy  to  treat  bronchogenic 
malignancy.  Suture  line  recurrence  may  be  related  to  lung 
preservation at the expense of adequate bronchial margins [3]. 
Therefore, Paulson and colleagues [19] recommended that the 
bronchial resection margins be at least 1.5 cm away from the 
tumor. The incidence of local recurrence has ranged from 5% 
to  51%  [7].  In  a  recent  study  comparing  sleeve  lobectomy 
with pneumonectomy  for NSCLC, Okada and  colleagues  [13] 
found  that  the  local  recurrence  rat e  w a s  l o w e r  a f t e r  b r o n c h o -
plastic  procedures.  In  our  study,  there  was  1  (5.2%)  locore-
gional  with  distant  recurrence  after  sleeve  lobectomy.
Van Schil [14] reported that nodal status was the most sig-
nificant  determinant  of  long-term  survival  after  sleeve  lobec-
tomy,  with  significantly  shorter  survival  in  patients  with  N2 
disease  than  in  those  with  N1  or  N0  disease.  It  has  been Sleeve Lobectomy versus Pneumonectomy for Lung Cancer
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shown  that  N2  disease  is  highly  predictive  of  distant  recur-
rences  [20]. 
CONCLUSION 
Sleeve  lobectomy  is  accepted  as  appropriate  for  selected 
patients  with  resectable  malignant  tumors  and  presents  an  al-
ternative to the otherwise unavoidable pneumonectomy, owing 
to  low  mortality  and  good  preservation  of  pulmonary 
function.
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